Q-omics provides the consensus-scored MIR23C profile across patient tissues and cancer cell-line models. MIR23C expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR23C is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MIR23C RNA expression shows 13,659 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where MIR23C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR23C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR23C survival associations across molecular data types. MIR23C RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR23C RNA expression–survival associations across cancer types. High MIR23C expression shows unfavorable associations in UCEC, KIRP, STAD and LIHC, but favorable associations in HNSC and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR23C RNA expression.
This table summarizes MIR23C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR23C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR23C shows lower tumor expression in ESCA and higher tumor expression in KIRC, LUAD, COAD, LUSC and PRAD. The KIRC box plot shows higher MIR23C RNA expression in tumor versus normal tissue (log2 FC = +0.652, t-test p < 0.001).
This table shows molecular features associated with MIR23C in patient tissues and cancer cell lines. In patient samples, MIR23C shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
